✦ LIBER ✦

Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors

✍ Scribed by Brady L. Stein; B. Douglas Smith

Book ID: 113773492
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 129 KB
Volume: 35
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.06.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chronic myeloid leukemia in the tyrosine

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?

✍ Alfonso Quintás-Cardama; Jorge Cortes 📂 Article 📅 2009 🏛 Current Science Inc. 🌐 English ⚖ 295 KB

Chronic Myeloid Leukemia in the Tyrosine

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

✍ Meetu Agrawal; Ravin J. Garg; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 212 KB

Outcome of allogeneic SCT in patients wi

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

✍ Oyekunle, Anthony; Zander, Axel R.; Binder, Mascha; Ayuk, Francis; Zabelina, Tat 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 229 KB

Class effects of tyrosine kinase inhibit

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

✍ Giles, F J; O'Dwyer, M; Swords, R 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 315 KB

Estimations of the increasing prevalence

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

✍ Xuelin Huang; Jorge Cortes; Hagop Kantarjian 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 889 KB

Intolerance to tyrosine kinase inhibitor

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : Definitions and clinical implications

✍ Javier Pinilla-Ibarz; Jorge Cortes; Michael J. Mauro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

## Abstract Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region‐Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long‐t